Oswaldo Cruz 116, e200634
The Evidence Here is exactly what the SELECT trial found: 17,604 participants enrolled, all with established cardiovascular disease, BMI of 27 or greater, and no diabetes Primary MACE event rate: 6.5 percent in the semaglutide group versus 8.0 percent in the placebo group Hazard ratio of 0.80 means a 20 percent relative reduction in the risk of heart attack, stroke, or cardiovascular death 95 percent confidence interval: 0.72 to 0.90, meaning the true effect falls within that range with high certainty P value less than 0.001, which is statistically decisive Mean follow-up: 39.8 months Mean weight loss with semaglutide: 9.4 percent of body weight Serious adverse events leading to discontinuation: 16.6 percent in the semaglutide group versus 8.2 percent in the placebo group That last number is a bit concerning
The Takeaway Yerba Mate Benefits Yerba mate shows promise for metabolic health, brain health, and beyondyet current evidence is limited and mostly preliminary
It is not bought or made up for click-bait purposes
Bovine lactoferrin ameliorates ferric nitrilotriacetate-induced renal oxidative damage in rats